British Biosimilar Association, Andrew Ellis
The British Biosimilar Association (BIA), a trade body representing biosimilar manufacturers in the UK, revealed that Andrew Ellis will become its new chair.
Ellis is currently director of secondary care at Teva UK and will retain this role alongside his work at the biosimilar organization, he replaces Kavya Gopal of Sandoz.
For the majority of his career, Ellis has worked within marketing and sales roles, with his current role focusing on market access for Teva’s treatments.
Teva is a member of BBA’s steering group and Ellis had already been an ‘active member’ prior to his installation as chair, according to director general, Warwick Smith.
Ellis said, “We are already seeing the real potential of biosimilars to transform the lives of patients with long-term and complex conditions.”
One such biosimilar is Humira (adalimumab), which is projected to save the UK’s NHS £300m ($388m) per year.